Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.04 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.27 +11.9% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.51 +1.2% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0% S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.04 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.27 +11.9% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.51 +1.2% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0%
Regulatory Routine +

MediPharm Labs Reminds Shareholders of Upcoming Annual and Special Meeting

MediPharm Labs Turns EBITDA Positive Amidst Revenue Contraction and Governance Shifts

By The Northwire Desk — AI Analysis May 28, 2026 · 08:00 LABS · 0.08 MEDIPHARM LABS CORP. J
Executive Summary
  • Meeting Notice: MediPharm Labs announced an Annual and Special Meeting of Shareholders scheduled for June 17, 2026.
  • Governance Changes: The Board proposes reducing directors from seven to five members and appointing MNP LLP as auditor. Voting deadline is June 15, 2026.
  • Financial Highlights Reiteration: The notice reiterates Q1 2026 performance: $9 million net revenue, positive adjusted EBITDA ($0.1M), and a cash balance of $9.9 million as at March 31, 2026.
  • Operational Metrics: Gross margins held at 37%. Operating expenses decreased 28% compared to Q4 2025. Germany revenue grew 14% sequentially.
  • International Expansion: Inaugural Beacon branded flower shipment to New Zealand completed; purchase orders secured in France and Brazil with manufacturing underway in Q2 2026.
  • Balance Sheet: Company remains virtually debt-free with outright ownership of two licensed production facilities valued at over $15 million.
Material Impact
  • News Timing: The most recent news (May 28, 2026) is a meeting reminder that summarizes financial data already released in the Q1 earnings report on May 13, 2026.
  • Information Redundancy: Since the core financial metrics ($9M revenue, positive EBITDA, $9.9M cash) were disclosed two weeks prior, this release does not introduce new market-moving data regarding performance.
  • Governance Impact: The proposal to reduce the Board from seven to five members is a minor operational change intended to streamline decision-making and potentially reduce overhead costs. It does not materially alter the company's strategic direction or risk profile significantly.
  • Confirmation of Turnaround: While routine, the reiteration of positive adjusted EBITDA reinforces the narrative established in May 13 that cost-cutting measures are working despite revenue headwinds.
  • Verdict: The news is Routine - Positive because it confirms stability and governance efficiency without presenting new catalysts or surprises relative to the May 13 earnings release.
LABS · Price
Company Overview
  • Company Profile: MediPharm Labs Corp. operates as a pharmaceutical-grade medical cannabis producer with a focus on regulated international markets rather than the volatile Canadian adult-use sector.
  • Flagship Project: The core strategy revolves around supplying GMP-certified medicinal cannabis to highly regulated markets including Germany, France, New Zealand, Brazil, and Australia.
  • Regulatory Moat: The company holds unique credentials including a Health Canada Drug Establishment License (DEL), EU-GMP certification, FDA site registration, and TGA approval in Australia. This positions them as a partner for clinical trials and pharmaceutical development rather than just flower sales.
  • US Opportunity: Following the U.S. rescheduling of cannabis from Schedule I to III (effective April 2026), MediPharm is positioned to supply API and clinical trial material, though this is a longer-term catalyst with no immediate P&L impact.
Read the original news release →

More from MEDIPHARM LABS CORP. J

May 13, 2026 · 07:30

MediPharm Labs scrapes to adjusted EBITDA profitability in Q1 2026, but a veteran affairs reimbursement cut looms large over its direct-to-patient business.

Earnings Apr 27, 2026 · 08:30

US Rescheduling Confirmed, But Canadian Revenue Headwinds Loom

Regulatory Mar 30, 2026 · 07:45

MediPharm Posts Margin Recovery and Steady International Growth, Yet Profitability Remains Elusive

Earnings Mar 25, 2026 · 19:05

MediPharm Delivers Margin Recovery and Near-Breakeven EBITDA as International Sales Offset Domestic Stagnation

Earnings Jan 19, 2026 · 08:00

MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO

Management Jan 13, 2026 · 18:47

Medipharm Labs signs Costa Rica supply agreement

M&A / Property